Eloralintide Study for Weight, Diabetes and Heart Risk in Adults
Tests eloralintide against placebo in adults with obesity, diabetes and heart risk.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Key facts
- Where
- Aracaju, Brasília, Campinas, Curitiba, Fortaleza, Porto Alegre, Recife, Rio de Janeiro, São Paulo, and Vitória, BrazilSee the 15 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 64 years old?
Source: NCT07900633, who can take part
Where in Brazil
- Centro de Pesquisa Clinica do CoracaoAracaju, BrazilNo longer taking part
- Centro de Pesquisa Clínica do BrasilBrasília, BrazilNo longer taking part
- Centro de Pesquisa Sao LucasCampinas, BrazilNo longer taking part
- Quanta Diagnóstico e TerapiaCuritiba, BrazilNo longer taking part
- Instituto de Ensino e Pesquisa Clinica do CearaFortaleza, BrazilNo longer taking part
- Private Practice - Dr.Miguel N. HissaFortaleza, BrazilNo longer taking part
- Hospital Moinhos de VentoPorto Alegre, BrazilNo longer taking part
- Nucleo de Pesquisa Clínica do Rio Grande do SulPorto Alegre, BrazilNo longer taking part
- Rede AME SaúdeRecife, BrazilNo longer taking part
- IBPClin - Instituto Brasil de Pesquisa ClínicaRio de Janeiro, BrazilNo longer taking part
- CEPIC - Centro Paulista de Investigação ClínicaSão Paulo, BrazilNo longer taking part
- CPCLINSão Paulo, BrazilNo longer taking part
- CPHosp Medicina, Ensino e Pesquisa (CPQuali)São Paulo, BrazilNo longer taking part
- Instituto de Pesquisa ClinicaSão Paulo, BrazilNo longer taking part
- CEDOESVitória, BrazilNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07900633EU 2026-525919-14-00
- Record updated
- 3 November 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
Inclusion: Have type 2 diabetes; Have a HbA1c value between ≥ 6.5% and ≤ 9.5% at screening; Are on stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening; Have an increased risk of cardiovascular events; Have a BMI ≥ 25.0 kg/m2 at screening; Have a stable body weight (<5% body weight change) for 90 days prior to screening; Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 60 days prior to screening:; acute myocardial infarction; stroke; hospitalization for congestive heart failure, or; coronary, peripheral, or carotid artery revascularization procedure; Have received treatment combining sulfonylurea and insulin within 90 days prior to screening; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification IV congestive heart failure.